^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    BCMA-targeted CAR-T immunotherapy

    Related drugs:
    1d
    A Phase I, Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Cellular Kinetics, Immunogenicity, Pharmacodynamics, and Preliminary Efficacy of AZD0120 in Participants With Multiple Myeloma (clinicaltrials.gov)
    P1, N=64, Recruiting, AstraZeneca | N=20 --> 64
    Enrollment change
    |
    AZD0120
    6d
    Safety and Efficacy of PRG-1801 in Recurrent/Refractory Primary Immune Thrombocytopenia (ITP) (clinicaltrials.gov)
    P1, N=6, Recruiting, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Trial primary completion date: Aug 2025 --> Dec 2026
    Trial primary completion date
    |
    cyclophosphamide • fludarabine IV
    8d
    Study of GC012F, CAR-T Therapy Targeting CD19 and BCMA in Chinese Participants With Relapsed or Refractory AL Amyloidosis (clinicaltrials.gov)
    P1, N=9, Recruiting, Gracell Biotechnologies (Shanghai) Co., Ltd.
    New P1 trial
    |
    AZD0120
    10d
    SLE-001: Descartes-08 for Patients With Systemic Lupus Erythematosus (clinicaltrials.gov)
    P2, N=6, Active, not recruiting, Cartesian Therapeutics | Recruiting --> Active, not recruiting | N=30 --> 6
    Enrollment closed • Enrollment change
    |
    Descartes-08
    10d
    TSCM-predominant allogeneic anti-BCMA CAR-T therapy for relapsed/refractory multiple myeloma: preclinical characterization and interim results from a phase 1 trial. (PubMed, Nat Commun)
    Here, we present the characterization and interim Phase I data for P-BCMA-ALLO1, a TSCM-predominant allogeneic CAR-T therapy targeting BCMA in heavily pretreated relapsed/refractory multiple myeloma...These data suggest that a TSCM cellular phenotype may offer significant advantages in efficacy, safety, and cellular persistence in the context of allogeneic CAR-T therapy. Clinical trial: NCT04960579.
    P1 data • Preclinical • Journal
    |
    CD8 (cluster of differentiation 8)
    |
    RG6538
    10d
    DC15-MM-01: Descartes-15 for Patients With Relapsed/Refractory Multiple Myeloma (clinicaltrials.gov)
    P1, N=4, Terminated, Cartesian Therapeutics | Trial completion date: Oct 2027 --> Nov 2025 | Active, not recruiting --> Terminated | Trial primary completion date: Dec 2026 --> Apr 2025; Phase 1 enrollment completed. Further clinical development terminated
    Trial completion date • Trial termination • Trial primary completion date
    11d
    Robust CD4 + CAR T cell Expansion Is Associated with Non-ICANS Neurotoxicities Following Ciltacabtagene Autoleucel. (PubMed, medRxiv)
    Finally, we characterize NINT associated CD4 + CAR T cell populations which are potential therapeutic targets for future exploration. Ciltacabtagene autoleucel associated non-ICANS neurotoxicities are driven by high CD4 + CAR T cell expansion exhibiting memory marker expression and upregulated inflammatory gene signaling pathways.
    Journal
    |
    CD4 (CD4 Molecule)
    |
    Carvykti (ciltacabtagene autoleucel)
    14d
    MCARTY: A New Study Evaluating the Activity of Modular CAR T for mYeloma (clinicaltrials.gov)
    P1, N=27, Recruiting, University College, London | Active, not recruiting --> Recruiting | Trial completion date: Dec 2035 --> Mar 2029 | Trial primary completion date: Dec 2025 --> Mar 2029
    Enrollment open • Trial completion date • Trial primary completion date
    20d
    Integrated clinical and single-cell profiling of BCMA CAR-T therapy in relapsed/refractory multiple myeloma. (PubMed, J Transl Med)
    Locally produced BCMA CAR-T is safe and effective in heavily pretreated R/R MM, inducing deep responses. scRNA-seq/TCR-seq findings highlight interplay of CAR-T heterogeneity, clonal adaptability, and immune regulation. CD8⁺ subset specialization and clonal persistence matter for durable responses; exhaustion and immunosuppression may cause relapse.
    Journal
    |
    CD8 (cluster of differentiation 8) • IFNG (Interferon, gamma) • IL6 (Interleukin 6)
    |
    Actemra IV (tocilizumab) • Abecma (idecabtagene vicleucel) • Carvykti (ciltacabtagene autoleucel)
    22d
    CARTITUDE-4: A Study Comparing JNJ-68284528, a CAR-T Therapy Directed Against B-cell Maturation Antigen (BCMA), Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexamethasone (DPd) in Participants With Relapsed and Lenalidomide-Refractory Multiple Myeloma (clinicaltrials.gov)
    P3, N=419, Active, not recruiting, Janssen Research & Development, LLC | Trial completion date: Sep 2036 --> Apr 2029
    Trial completion date • IO biomarker
    |
    lenalidomide • bortezomib • cyclophosphamide • pomalidomide • Darzalex Faspro (daratumumab and hyaluronidase-fihj) • Carvykti (ciltacabtagene autoleucel)
    23d
    P-BCMA-ALLO1-001: P-BCMA-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With Multiple Myeloma (clinicaltrials.gov)
    P1, N=275, Recruiting, Poseida Therapeutics, Inc. | Trial completion date: Dec 2039 --> Mar 2042 | Trial primary completion date: Dec 2027 --> Mar 2029
    Trial completion date • Trial primary completion date
    |
    RG6538 • rimiducid (AP1903)
    24d
    MonumenTAL-8: A Study of Ciltacabtagene Autoleucel and Talquetamab for the Treatment of Participants With High-Risk Multiple Myeloma (clinicaltrials.gov)
    P2, N=11, Active, not recruiting, Janssen Research & Development, LLC | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    Carvykti (ciltacabtagene autoleucel) • Talvey (talquetamab-tgvs)